HERIZON-BTC-01: Zanidatamab for HER2-Positive BTC

By Shubham Pant, MD - Last Updated: January 27, 2025

At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Shubham Pant, MD, of The University of Texas MD Anderson Cancer Center, offered insights on the key findings and preliminary data from the HERIZON-BTC-01 study that highlighted zanidatamab’s efficacy and safety compared to standard-of-care therapies in HER2-positive BTC.

Safety, Efficacy of HER2 Therapy for Patients With Biliary Tract Cancers

Jessica GangaBile Duct Cancer | May 12, 2025

In a systematic review, researchers found that several anti-HER2 therapies may benefit patients with biliary tract cancers.

Patients With HER2-Amplified BTC Can Benefit From HER2-Targeted Therapy

Emily MenendezBile Duct Cancer | May 7, 2025

A multivariate analysis revealed HER2-targeted therapy to be an independent prognostic factor for OS.

Detecting Early Recurrence With ctDNA in BTC After Curative Resection

Richard Kim, MDBile Duct Cancer | March 22, 2025

Dr. Kim discusses how ctDNA compares to traditional imaging and how findings can affect adjuvant treatment decisions for BTC.

Risk for Choledocholithiasis Higher in Older Adult Patients With Cholangiocarcinoma

Emily MenendezBile Duct Cancer | March 11, 2025

Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.

ctDNA Detection Outperforms Standard Surveillance in Predicting BTC Recurrence

Emily MenendezBile Duct Cancer | February 20, 2025

Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.

HERIZON-BTC-01: Zanidatamab for HER2-Positive BTC

Related Posts